Source: International Congress 2015 – Non-small cell lung cancer (NSCLC): sequence, timing, and modality of multi-line therapies



Rating:

Share or cite this content

Citations should be made in the following way:
Pascale Tomasini (Marseille, France). Combating acquired resistance: are rebiopsies needed for guiding multi-line therapies?. International Congress 2015 – Non-small cell lung cancer (NSCLC): sequence, timing, and modality of multi-line therapies

Member's Comments

No comment yet.

Related content which might interest you: MDR-TB management: what is new? Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination Year: 2012 Second-line injectables: are they essential to treat MDR/XDR-TB cases? Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008 Improved diagnostics and diagnostic approaches: The role in the fight to emerging infectious diseases (EID) and antimicrobial resistance (AMR) Source: Postgraduate course 2021: PG7 - Postgraduate course : Emerging infectious diseases and antimicrobial resistance: diagnostics, treatments, vaccines and other preventive and/or therapeutic interventions Year: 2021 Advances in targeted therapy: the clinicians point of view Source: International Congress 2014 – Update on lung cancer biology for clinicians Year: 2014 Second- and third-line therapies: what are the best options? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007 Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Source: Eur Respir J 2013; 42: 1449-1453 Year: 2013 Better diagnostics for targeted antibiotic therapy Source: Virtual Congress 2020 – Antibiotic resistance: the way forward Year: 2020 Preventing and managing antimicrobial resistance: imperative for chest physicians Source: Eur Respir J 2011; 37: 978-981 Year: 2011 Tuberculosis elimination, patients' lives and rational use of new drugs: revisited Source: Eur Respir J 2016; 47: 664-667 Year: 2016 Do we need new antibiotics? Source: Annual Congress 2009 - Antibiotics and the lung Year: 2009 Bronchiectasis: new therapies and perspectives Source: International Congress 2018 – Bronchiectasis: new insights in diagnosis and treatment Year: 2018 EGFR-inhibition: resistance mechanisms and new strategies Source: International Congress 2014 – Update on lung cancer biology for clinicians Year: 2014 Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable? Source: Eur Respir J 2012; 40: 9-11 Year: 2012 Getting approval for new therapeutic medical devices versus drugs: are the differences justified? Source: Eur Respir Rev 2016; 25: 223-226 Year: 2016